Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.
about
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.An economic analysis of poliovirus risk management policy options for 2013-2052Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.Cell-Based High-Throughput Screening Assay Identifies 2',2'-Difluoro-2'-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent.Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.Poliovirus vaccination during the endgame: insights from integrated modeling.Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status.Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.Evolution of echovirus 11 in a chronically infected immunodeficient patient.Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
P2860
Q33873406-DF317AF0-8DB5-4EA1-B443-7EABDC1F633CQ35779660-244D506A-9235-4D2D-ABBB-F465DFB85D55Q35787304-0A240726-D79D-40F8-AAEE-2261B0A52080Q35968325-09DFF033-149D-4213-AFA7-AA63B7694D1DQ36031421-52AC95FF-BEC6-46B2-9301-8F8DEF42A773Q36035498-021807CC-8982-41E6-A798-D428125D51B8Q36161679-EDFA192C-9065-4E12-B330-8DD7C9A0C904Q37542082-F46B3A8D-D82B-4E5C-8C62-E4252F5E82A4Q38796753-7935EB54-C118-4CEE-AE00-0B3E48DF3138Q39258694-C6D387F8-FF0A-41B1-994C-340ED4335279Q40071746-E2D18B99-F5C2-40A9-BD27-D487E7AF8B72Q40071754-3672B08D-C8B6-44D2-B715-033E21F3C6A8Q41921219-3F9034DF-C7E6-45F5-A208-B5F1CD6B79DDQ47110369-427A9F4D-222A-4D29-A9C1-ABBA2C8DABC1Q47556747-79A03259-ED25-4667-A361-3B47450E21E3Q52648772-5FC4F12A-7868-4326-B493-295368E18678Q55344705-278CCB44-F8C6-4F34-9E1A-4BAC343A6281Q58791913-C819BB68-9BEF-4075-B8EA-F13A4C2C671B
P2860
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@ast
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@en
type
label
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@ast
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@en
prefLabel
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@ast
Modeling the prevalence of imm ...... l benefits of antiviral drugs.
@en
P2860
P50
P1476
Modeling the prevalence of imm ...... al benefits of antiviral drugs
@en
P2860
P2888
P356
10.1186/S12879-015-1115-5
P577
2015-09-17T00:00:00Z
P5875
P6179
1035853563